Literature DB >> 24100522

Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.

Trine Tramm1, Guido Hennig, Marianne Kyndi, Jan Alsner, Flemming Brandt Sørensen, Simen Myhre, Therese Sørlie, Jens Overgaard.   

Abstract

Gene expression analysis on messenger RNA (mRNA) purified from formalin-fixed, paraffin-embedded tissue is increasingly used for research purposes. Tissue heterogeneity may question specificity and interpretation of results from mRNA isolated from a whole slide section, and thresholds for minimal tumor content in the paraffin block or macrodissection are used to avoid contamination from non-neoplastic tissue. The aim was to test if mRNA from tissue surrounding breast cancer affected quantification of estrogen receptor α (ESR1), progesterone receptor (PGR) and human epidermal growth factor receptor 2 (ERBB2), by comparing gene expression from whole slide and tumor-enriched sections, and correlating gene expression from whole slide sections with corresponding immunohistochemistry. Gene expression, based on mRNA extracted from a training set (36 paraffin blocks) and two validation sets (133 + 1,083 blocks), were determined by quantitative reverse transcription polymerase chain reaction for all samples, as well as by microarray for 133 validation samples. In the training set, agreement between high vs. low mRNA expression from whole slide and tumor-enriched sections was absolute for ESR1 and ERBB2, and 83 % for PGR. Overall agreements, when comparing mRNA expression to immunohistochemistry, were 100 % (ERBB2), 89 % (ESR1) and 83 % (PGR), which was confirmed in the validation sets. Percentage of tumor in the sections did not influence the results. In conclusion, reliable quantification of ESR1, PGR and ERBB2 mRNA expression can be obtained from a whole slide section, and correlates well with immunohistochemistry. Prior removal of surrounding tissue was found to be unnecessary even with minimal tumor content in the section.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100522     DOI: 10.1007/s00428-013-1486-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Authors:  Martin Filipits; Margaretha Rudas; Raimund Jakesz; Peter Dubsky; Florian Fitzal; Christian F Singer; Otto Dietze; Richard Greil; Andrea Jelen; Paul Sevelda; Christa Freibauer; Volkmar Müller; Fritz Jänicke; Marcus Schmidt; Heinz Kölbl; Achim Rody; Manfred Kaufmann; Werner Schroth; Hiltrud Brauch; Matthias Schwab; Peter Fritz; Karsten E Weber; Inke S Feder; Guido Hennig; Ralf Kronenwett; Mathias Gehrmann; Michael Gnant
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

2.  Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?

Authors:  Gábor Cserni; Monika Francz; Endre Kálmán; Gyöngyi Kelemen; Detre Csaba Komjáthy; Ilona Kovács; Janina Kulka; László Sarkadi; Nóra Udvarhelyi; László Vass; András Vörös
Journal:  Pathol Oncol Res       Date:  2011-01-26       Impact factor: 3.201

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment.

Authors:  Gunilla Chebil; Pär-Ola Bendahl; Mårten Fernö
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

5.  The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.

Authors:  Xiao-Jun Ma; Susan G Hilsenbeck; Wilson Wang; Li Ding; Dennis C Sgroi; Richard A Bender; C Kent Osborne; D Craig Allred; Mark G Erlander
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.

Authors:  Kasper Toustrup; Brita Singers Sørensen; Pernille Lassen; Carsten Wiuf; Jan Alsner; Jens Overgaard
Journal:  Radiother Oncol       Date:  2011-10-11       Impact factor: 6.280

7.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Authors:  Marianne Kyndi; Flemming B Sørensen; Helle Knudsen; Marie Overgaard; Hanne Melgaard Nielsen; Jens Overgaard
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

8.  Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.

Authors:  Paul Roepman; Hugo M Horlings; Oscar Krijgsman; Marleen Kok; Jolien M Bueno-de-Mesquita; Richard Bender; Sabine C Linn; Annuska M Glas; Marc J van de Vijver
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

9.  RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods.

Authors:  Kerstin Bohmann; Guido Hennig; Uwe Rogel; Christopher Poremba; Berit Maria Mueller; Peter Fritz; Stephan Stoerkel; Karl-L Schaefer
Journal:  Clin Chem       Date:  2009-07-17       Impact factor: 8.327

10.  Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.

Authors:  M Kyndi; F B Sørensen; H Knudsen; M Overgaard; H M Nielsen; J Andersen; J Overgaard
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

View more
  3 in total

1.  Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.

Authors:  Rou Chen; Qingzhou Guan; Jun Cheng; Jun He; Huaping Liu; Hao Cai; Guini Hong; Jiahui Zhang; Na Li; Lu Ao; Zheng Guo
Journal:  Oncotarget       Date:  2017-01-24

2.  Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Authors:  Christopher Poremba; Jennifer Uhlendorff; Berit M Pfitzner; Guido Hennig; Kerstin Bohmann; Hans Bojar; Veit Krenn; Jan C Brase; Franziska Haufe; Manuela Averdick; Manfred Dietel; Ralf Kronenwett; Carsten Denkert
Journal:  Virchows Arch       Date:  2014-09-14       Impact factor: 4.064

3.  Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.

Authors:  Kerstin Hartmann; Kornelia Schlombs; Mark Laible; Claudia Gürtler; Marcus Schmidt; Ugur Sahin; Hans-Anton Lehr
Journal:  Diagn Pathol       Date:  2018-10-20       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.